Phase 2 iMMagine-1: 97% response for Anito-cel

Kite Pharma (Gilead)/Anito-cel (anitocabtagene autoleucel)

Phase 2 iMMagine-1 trial with all 117 patients achieved 97% overall response rate. Complete/stringent complete response rate 68%, with 93% MRD negativity and median follow-up of 12.6 months; no delayed neurotoxicities observed.

• ORR: 97% (114/117 patients)
• CR/sCR: 68% (79/117 patients)
• MRD-negative: 93.3% of evaluable patients
• Median follow-up: 12.6 months
• No delayed neurotoxicity or immune-mediated complications